SUPN

Oct 19, 4:02 PMNasdaq posts November 2 merger timetable, lifting Supernus 5% alongside Indivior during regular trading

Peers: ALKS NBIX ACAD AXSM COLL HRMY INDV JAZZ AMRX BIIB

| Held by: IJR VTI IWM VB VBR VXF SPSM IWN DFAS DFAT

Index	RUT
Market Cap	2.35B
Enterprise Value	2.01B
Income	-109.89M
Sales	830.44M
Book/sh	17.73
Cash/sh	6.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	778
IPO	May 01, 2012

P/E	-
Forward P/E	9.36
PEG	0.50
P/S	2.82
P/B	2.27
P/C	6.30
P/FCF	124.83
EV/EBITDA	53.67
EV/Sales	2.42
Quick Ratio	1.84
Current Ratio	2.08
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.91
EPS next Y	4.30
EPS next Q	0.56
EPS this Y	-21.64%
EPS next Y	69.82%
EPS next 5Y	18.63%
EPS past 3/5Y	- -
Sales past 3/5Y	2.52% 6.68%
EPS Y/Y TTM	-264.42%
Sales Y/Y TTM	24.85%
EPS Q/Q	-353.07%
Sales Q/Q	32.40%
Earnings	Oct 29 AMC
EPS/Sales Surpr.	24.52% 6.70%

Insider Own	6.34%
Insider Trans	0.00%
Inst Own	102.17%
Inst Trans	1.45%
ROA	-7.82%
ROE	-10.49%
ROIC	-10.36%
Gross Margin	75.83%
Oper. Margin	-7.73%
Profit Margin	-13.23%
SMA20	-4.26%
SMA50	-7.48%
SMA200	-15.48%
Trades

Shs Outstand	58.16M
Shs Float	54.53M
Short Float	9.14%
Short Ratio	6.25
Short Interest	4.99M
52W High	59.68 -32.50%
52W Low	37.54 7.31%
Volatility	5.90% 3.94%
ATR (14)	1.72
RSI (14)	41.76
Beta	0.52
Rel Volume	0.97
Avg Volume	798.30K
Volume	517,081

Perf Week	-4.11%
Perf Month	-5.83%
Perf Quarter	-14.18%
Perf Half Y	-17.99%
Perf YTD	-18.94%
Perf Year	-21.91%
Perf 3Y	65.71%
Perf 5Y	34.73%
Perf 10Y	92.94%
Recom	1.50
Target Price	60.50
Prev Close	39.84
Price	40.28
Change %	1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight	$65
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$42
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $36
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight	$57
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$41 → $36
Jan-03-23	Resumed	Jefferies	Buy	$44 → $45
Dec-01-21	Resumed	Jefferies	Buy	$40 → $44
Apr-13-21	Upgrade	Jefferies	Hold → Buy	$25 → $40
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$25 → $31
Jun-15-20	Resumed	Jefferies	Hold	$24
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold	$55 → $23
Nov-06-19	Downgrade	Jefferies	Buy → Hold	$46 → $23
Nov-12-18	Reiterated	B. Riley FBR	Buy	$68 → $65
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy	$54
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy	$50 → $54
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy	$47
Oct-19-17	Initiated	FBR & Co.	Buy	$53
Sep-19-17	Downgrade	Stifel	Buy → Hold	$47

Show Previous Ratings

Oct-19-26 08:30AM	Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 (GlobeNewswire) +5.17%
Sep-25-26 07:38AM	Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-02-26 04:30PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
Aug-31-26 08:30AM	Chloe Kim Teams Up with Qelbree, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD (GlobeNewswire)
Aug-07-26 05:06PM	Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
01:05AM	Loading…
Aug-05-26 01:05AM	Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +8.46%
Aug-04-26 07:57AM	Supernus and Indivior merge to create scaled, CNS-focused entity (Pharmaceutical Technology) -5.98%
Aug-03-26 01:41PM	Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:28AM	Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
08:22AM	Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
06:47AM	Supernus: Q2 Earnings Snapshot (Associated Press)
06:35AM	Supernus Announces Second Quarter 2026 Financial Results (GlobeNewswire)
06:30AM	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale (GlobeNewswire)
Jul-22-26 05:05PM	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 (GlobeNewswire)
Jul-14-26 08:30AM	Supernus Celebrates Five-Year Anniversary of Qelbree FDA Approval, Continuing to Deliver on Real-World Experience in ADHD (GlobeNewswire)
04:30PM	Loading…
May-27-26 04:30PM	Supernus Pharmaceuticals to Participate in June Investor Conferences (GlobeNewswire)
May-06-26 05:00PM	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference (GlobeNewswire)
May-05-26 08:19PM	Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
04:42PM	Supernus: Q1 Earnings Snapshot (Associated Press)
04:05PM	Supernus Announces First Quarter 2026 Financial Results (GlobeNewswire)
Apr-22-26 04:15PM	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 (GlobeNewswire)
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Feb-25-26 08:30AM	Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) +5.67%
01:07AM	Supernus Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-24-26 10:30PM	Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +5.15%
09:55PM	Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:08PM	Supernus: Q4 Earnings Snapshot (Associated Press Finance)
04:21PM	Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales (StockStory)
04:05PM	Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
06:15PM	Loading…
Feb-23-26 06:15PM	Supernus Pharmaceuticals to Participate in March Investor Conferences (GlobeNewswire)
Feb-22-26 10:08PM	Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-17-26 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline (Zacks)
Feb-16-26 11:04PM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Feb-12-26 04:35PM	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 (GlobeNewswire)
Feb-06-26 11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Dec-19-25 06:57AM	Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 (Insider Monkey)
Dec-03-25 04:05PM	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference (GlobeNewswire)
Nov-21-25 04:06PM	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
11:00AM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) (StockStory)
Nov-12-25 04:05PM	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-11-25 12:36AM	5 Must-Read Analyst Questions From Supernus Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-06-25 08:07AM	Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position (Insider Monkey)
Nov-05-25 12:26PM	Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today (StockStory) -17.35%
08:37AM	SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs (StockStory)
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com)
Nov-04-25 08:30PM	Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:18PM	Supernus: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3 (StockStory)
04:01PM	Supernus Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-02-25 10:01PM	Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-30-25 02:02PM	BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View (Zacks)
10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
12:00PM	Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy (Zacks)
09:35AM	Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls (The Fly)
Oct-28-25 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline (Zacks)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-27-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-24-25 10:33AM	Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key (Zacks)
Oct-22-25 12:10PM	Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-21-25 05:00PM	Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (GlobeNewswire)
Oct-16-25 03:23AM	Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP (Zacks)
Oct-15-25 03:08PM	Can 4 Relative Price Strength Stocks Defy Market Swings? (Zacks)
Oct-13-25 12:00PM	Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know (Zacks)
Oct-12-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines (StockStory)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-09-25 12:05PM	Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know (StockStory)
Sep-25-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice (Zacks)
Sep-23-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-18-25 09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-16-25 12:02AM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Aug-27-25 04:15PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-25 12:12AM	5 Insightful Analyst Questions From Supernus Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:43PM	SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade (StockStory)
Aug-11-25 08:00AM	Here's Third Avenue Small-Cap Value Fund's Update on Supernus Pharmaceuticals (SUPN) (Insider Monkey)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-06-25 01:20PM	Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today (StockStory) +13.08%
03:27AM	Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... (GuruFocus.com)
Aug-05-25 08:30PM	Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:18PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales (StockStory)
05:32PM	Supernus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Supernus Announces Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-03-25 11:08PM	Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect (StockStory)
Aug-01-25 07:09AM	Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics (Pharmaceutical Technology)
Jul-31-25 10:48AM	Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
08:44AM	Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics (GlobeNewswire)
Jul-30-25 04:05PM	Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)
12:16PM	Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today (StockStory)
Jul-28-25 10:24AM	Biogen Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
08:25AM	Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer (GlobeNewswire)
Jul-24-25 11:33PM	Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) (StockStory)
Jul-22-25 04:30PM	Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 (GlobeNewswire)
Jul-18-25 03:10PM	Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today (StockStory)
Jul-14-25 12:31AM	1 Stock Under $50 with Exciting Potential and 2 to Turn Down (StockStory)
Jun-30-25 01:43PM	Sage to lay off most staff amid Supernus buyout (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khattar Jack A.	President, CEO	Aug 12 '26	Option Exercise	0.00	29,849	0	1,270,993	Aug 14 05:12 PM
Rubin Jonathan	SVP, Chief Medical Officer	Aug 12 '26	Option Exercise	0.00	750	0	14,342	Aug 14 05:11 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 12 '26	Option Exercise	0.00	2,500	0	19,795	Aug 14 05:11 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Aug 12 '26	Option Exercise	0.00	1,650	0	20,341	Aug 14 05:10 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Aug 12 '26	Option Exercise	0.00	1,250	0	9,733	Aug 14 05:09 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Option Exercise	38.51	50,000	1,925,537	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Option Exercise	33.62	50,000	1,681,205	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Option Exercise	39.40	7,250	285,650	24,294	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Sale	50.30	50,000	2,514,886	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Sale	50.28	50,000	2,513,925	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Sale	49.60	7,250	359,621	17,044	Mar 18 05:18 PM
PADMANABH P BHATT	Officer	Mar 17 '26	Proposed Sale	50.21	57,250	2,874,522		Mar 17 04:29 PM
PADMANABH P BHATT	Officer	Mar 16 '26	Proposed Sale	49.91	50,000	2,495,500		Mar 16 04:38 PM
Khattar Jack A.	President, CEO	Mar 13 '26	Sale	50.37	35,000	1,763,124	958,100	Mar 16 04:08 PM
Hudson Frederick M.	Director	Mar 12 '26	Sale	50.61	5,369	271,725	60,413	Mar 16 04:07 PM
THE KBT TRUST U/A DTD 12/30/20	Director	Mar 13 '26	Proposed Sale	50.46	35,000	1,766,100		Mar 13 04:22 PM
FREDERICK M HUDSON	Director	Mar 12 '26	Proposed Sale	50.62	5,369	271,752		Mar 12 04:06 PM
WILLIAM TODD HORICH	Officer	Mar 10 '26	Proposed Sale	55.00	4,439	244,145		Mar 10 04:18 PM
Khattar Jack A.	President, CEO	Mar 06 '26	Option Exercise	0.00	38,640	0	1,245,218	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 06 '26	Option Exercise	0.00	3,750	0	21,856	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 09 '26	Sale	53.65	1,623	87,074	18,440	Mar 10 04:13 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Mar 06 '26	Option Exercise	0.00	6,000	0	9,682	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 06 '26	Option Exercise	0.00	7,500	0	9,991	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 10 '26	Sale	55.00	4,439	244,145	0	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 09 '26	Sale	54.00	4,438	239,652	4,439	Mar 10 04:12 PM
WILLIAM TODD HORICH	Officer	Mar 09 '26	Proposed Sale	54.00	4,438	239,652		Mar 09 04:43 PM
FRANK MOTTOLA	Officer	Mar 09 '26	Proposed Sale	53.65	1,623	87,074		Mar 09 04:16 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Option Exercise	25.30	7,905	199,996	36,064	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 05 '26	Sale	53.71	10,000	537,100	28,159	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Sale	53.00	8,787	465,711	27,277	Mar 09 04:06 PM
GEORGES GEMAYEL	Director	Mar 06 '26	Proposed Sale	53.01	8,787	465,771		Mar 06 04:24 PM
GEORGES GEMAYEL	Director	Mar 05 '26	Proposed Sale	53.71	10,000	537,117		Mar 05 04:04 PM
GEMAYEL GEORGES	Director	Feb 23 '26	Option Exercise	12.98	15,000	194,700	33,684	Feb 25 04:36 PM
Sensenig Bethany	Director	Feb 19 '26	Option Exercise	0.00	4,475	0	4,475	Feb 23 04:39 PM
Sensenig Bethany	Director	Feb 19 '26	Sale	51.01	4,475	228,265	0	Feb 23 04:39 PM
BETHANY SENSENIG	Director	Feb 19 '26	Proposed Sale	50.20	4,475	224,645		Feb 19 04:22 PM
Hudson Frederick M.	Director	Jan 09 '26	Option Exercise	12.98	15,000	194,700	61,307	Jan 12 04:09 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Option Exercise	28.82	20,000	576,500	30,496	Dec 22 04:04 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Sale	50.41	20,000	1,008,150	15,496	Dec 22 04:04 PM
FRANK MOTTOLA	Officer	Dec 19 '25	Proposed Sale	49.28	20,000	985,600		Dec 19 04:23 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Option Exercise	0.00	1,500	0	15,218	Dec 19 04:05 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Sale	44.44	710	31,552	14,508	Dec 19 04:05 PM
NEWHALL CHARLES W III	Director	Nov 21 '25	Option Exercise	12.98	15,000	194,700	119,644	Nov 24 06:16 PM

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

FounderMr. Jack A. Khattar M.B.A.

Senior VP & CFOMr. Timothy C. Dec

Chief Scientific Officer & Senior VP of Intellectual PropertyDr. Padmanabh P. Bhatt Ph.D.

Senior VP & Chief Technology Operations OfficerMr. Frank Mottola

M.D.Dr. Jonathan Rubin M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Supernus Pharmaceuticals Inc

Upgrade your Finviz experience